<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009683</url>
  </required_header>
  <id_info>
    <org_study_id>METC 13-2-033.3</org_study_id>
    <nct_id>NCT02009683</nct_id>
  </id_info>
  <brief_title>Multimodality Prediction of Success of Atrial Fibrillation Rhythm Control Strategy</brief_title>
  <acronym>MULTI-AF</acronym>
  <official_title>Multimodality Prediction of Success of Atrial Fibrillation Rhythm Control Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators aim to build a model to predict the maintenance of sinus&#xD;
      rhythm (SR) after successful direct current cardioversion (DCC) incorporating standard&#xD;
      predictors such as echocardiographic parameters, clinical parameter and 12-lead ECG&#xD;
      parameters and new parameters, including 17-lead ECG, Oesophageal-ECG and single nucleotide&#xD;
      polymorphisms (SNPs). Using this novel integrated prediction model will help in the&#xD;
      identification of patients who will maintain SR after cardioversion. Another innovative&#xD;
      aspect of our study is the use of daily rhythm monitoring using a versatile device&#xD;
      (MyDiagnostickÂ®). The clinical impact this study will have is that it helps the cardiologist&#xD;
      to make a patient tailored strategy in the treatment of AF as advocated by the guidelines and&#xD;
      to prevent exposing patients not likely to maintain SR to the potentially harmful side-effect&#xD;
      of a rhythm-control strategy.&#xD;
&#xD;
      Primary objectives To show that a model incorporating the novel predictors 17-lead ECG,&#xD;
      Oesophageal-ECG and SNPs is superior to existing models in predicting maintenance of sinus&#xD;
      rhythm after successful DCC in patients with persistent AF.&#xD;
&#xD;
      Secondary objectives To assess the predictive value of new predictors (the Oesophageal-ECG,&#xD;
      17-lead ECG and SNPs) for maintenance of SR after successful DCC separately.&#xD;
&#xD;
      To assess the predictive value of new predictors (the Oesophageal-ECG, 17-lead ECG and SNPs)&#xD;
      for time to recurrence of AF.&#xD;
&#xD;
      To assess the predictive value of predictors with respect to complete failure of&#xD;
      cardioversion.&#xD;
&#xD;
      To assess the predictive value of predictors with respect to cardiovascular morbidity.&#xD;
&#xD;
      Hypothesis The investigators hypothesise that a model incorporating the novel predictors the&#xD;
      17-leads ECG, Oesophageal-ECG and SNPs performs significantly better than existing models&#xD;
      using only clinical, echocardiographic and ECG parameters on a standard 12-lead ECG in&#xD;
      predicting maintenance of SR after successful DCC. In addition the investigators hypothesise&#xD;
      that Oesophageal-ECG is the best single predictor for maintenance of SR after successful DCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance of sinus rhythm after successful direct current cardioversion</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure of direct current cardioversion</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation for cardiovascular events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Atrial Fibrillation</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood biomarkers and SNPs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with persistent atrial fibrillation scheduled for direct current cardioversion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Haemodynamic stable patients with persistent AF scheduled for DCC.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Patients &gt; 18 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atrial flutter at time of DCC.&#xD;
&#xD;
          -  Patients with known oesophageal disease.&#xD;
&#xD;
          -  Patients with previous operations on throat or oesophagus.&#xD;
&#xD;
          -  Postoperative atrial fibrillation.&#xD;
&#xD;
          -  Patients with previous ablation for AF.&#xD;
&#xD;
          -  Previous inclusion in this study.&#xD;
&#xD;
          -  Patients on anti-arrhythmic drugs (AAD).&#xD;
&#xD;
          -  Patients with pacemakers unable to detect AF and with a regular paced rhythm during&#xD;
             AF.&#xD;
&#xD;
          -  Planned ablation for AF.&#xD;
&#xD;
          -  Myocardial infarction within the last 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H Crijns, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theo Lankveld, MD</last_name>
    <phone>+31433871611</phone>
    <email>theo.lankveld@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harry J Crijns, Md, PhD</last_name>
      <phone>043-3875091</phone>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

